1-3 of 3
Brian Koss
Close
Sort by
Journal Articles

PHF19 promotes multiple myeloma tumorigenicity through PRC2 activation and broad H3K27me3 domain formation

Zhihong Ren, Jeong Hyun Ahn, Hequn Liu, Yi-Hsuan Tsai, Natarajan V. Bhanu, Brian Koss, David F. Allison, Anqi Ma, Aaron J. Storey, Ping Wang, Samuel G. Mackintosh, Ricky D. Edmondson, Richard W. J. Groen, Anton C. Martens, Benjamin A. Garcia, Alan J. Tackett, Jian Jin, Ling Cai, Deyou Zheng, Gang Greg Wang
Journal: Blood
Blood (2019) 134 (14): 1176–1189.
https://doi.org/10.1182/blood.2019000578
Published: 2019
Includes: Supplemental data
Journal Articles

The Metabolic Phenotype of Myeloma Plasma Cells Differs Between Active and Residual Disease States

Brian Koss, Whitney Tevebaugh, Brian A Walker, PhD, Carolina Schinke, MD, Frits van Rhee, MD PhD, Maurizio Zangari, MD, Sharmilan Thanendrarajan, MD, Faith E Davies, MD, Joshua Epstein, DSc, Shmuel Yaccoby, PhD, Gareth J Morgan, MD PhD, Sarah K. Johnson, PhD
Journal: Blood
Blood (2016) 128 (22): 4438.
https://doi.org/10.1182/blood.V128.22.4438.4438
Published: 2016
Journal Articles

Requirement for antiapoptotic MCL-1 in the survival of BCR-ABL B-lineage acute lymphoblastic leukemia

Brian Koss, Jeffrey Morrison, Rhonda M. Perciavalle, Harpreet Singh, Jerold E. Rehg, Richard T. Williams, Joseph T. Opferman
Journal: Blood
Blood (2013) 122 (9): 1587–1598.
https://doi.org/10.1182/blood-2012-06-440230
Published: 2013
Includes: Supplemental data